Latest news with #SCD-044
New Indian Express
4 days ago
- Business
- New Indian Express
Sun Pharma shares plunge as its much touted psoriasis drug trial fails
CHENNAI: Shares of India's largest drug maker Sun Pharmaceutical Industries fell almost 1% on main stock exchanges on Wednesday following the company's announcement of a disappointing trial results of its much expected novel drug for psoriasis. The company said in a statement on Tuesday that it is discontinuing further development of its investigational drug SCD-044, a novel orally bioavailable anti-psoriasis drug following disappointing Phase 2 trial results. This investigational drug was tested for both psoriasis and atopic dermatitis indications. The company said that the trials (double-blind, placebo-controlled Phase 2 trial evaluated the efficacy and safety) were conducted in 263 patients with moderate to severe plaque psoriasis. The primary endpoint was the proportion of patients achieving a 75% reduction in the psoriasis area. The trial failed to meet this endpoint, although no major safety or tolerability issues were reported. 'While we are disappointed with the top-line results of the clinical trials, we would like to thank all the psoriasis and atopic dermatitis patients, the healthcare professionals and administrators who participated in these pivotal clinical trials,' said Dr. Marek Honczarenko, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Economic Times
4 days ago
- Business
- Economic Times
Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
Live Events Surprise FDA inspection at Halol unit About the drug and its target conditions (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Sun Pharma Advanced Research Company (SPARC), a unit of India's largest drug maker Sun Pharmaceutical Industries , tumbled as much as 20% on Wednesday to Rs 156.50 on the BSE after the company disclosed that its investigational drug SCD-044 failed to meet the main goals in late-stage clinical trials for psoriasis and atopic a filing released post-market hours on Tuesday, SPARC said, 'SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD).""SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16, respectively,' the company company further added, 'SPARC and SPIL will evaluate the appropriate next steps for SCD-044.'SPARC confirmed that, given the failure to meet primary endpoints, the development of the drug, also known as Vibozilimod, is being discontinued, and no further clinical trials are planned. The setback is significant as the drug was seen as a key asset in the company's speciality the past year, SPARC shares have declined about 3%, underperforming the benchmark Sensex, which has risen roughly 12% during the same CNBC-TV18 reported on Wednesday that a surprise inspection was underway at Sun Pharma's Halol facility, one of its largest manufacturing units, by three inspectors from the U.S. Food and Drug Halol unit was last inspected in May 2022 and is currently under an import alert following a warning letter from the was being developed as a treatment for psoriasis and atopic dermatitis, two chronic inflammatory skin conditions. Psoriasis is marked by raised, scaly plaques on the skin due to accelerated skin cell growth, often affecting the elbows, knees, scalp, and trunk. Atopic dermatitis, or eczema, typically involves dry, itchy, and inflamed skin, often beginning in childhood but potentially affecting people at any failure of the Phase 2 studies now casts uncertainty over SPARC's speciality drug pipeline, with investors and analysts awaiting further clarity on the company's next steps.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Time of India
4 days ago
- Business
- Time of India
Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
Shares of Sun Pharma Advanced Research Company (SPARC), a unit of India's largest drug maker Sun Pharmaceutical Industries , tumbled as much as 20% on Wednesday to Rs 156.50 on the BSE after the company disclosed that its investigational drug SCD-044 failed to meet the main goals in late-stage clinical trials for psoriasis and atopic dermatitis. In a filing released post-market hours on Tuesday, SPARC said, 'SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD)." "SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16, respectively,' the company said. The company further added, 'SPARC and SPIL will evaluate the appropriate next steps for SCD-044.' SPARC confirmed that, given the failure to meet primary endpoints, the development of the drug, also known as Vibozilimod, is being discontinued, and no further clinical trials are planned. The setback is significant as the drug was seen as a key asset in the company's speciality pipeline. Also read: Flipkart exits Aditya Birla Fashion and Retail in Rs 582 crore bulk deal; ABFRL stock tumbles 11% Over the past year, SPARC shares have declined about 3%, underperforming the benchmark Sensex, which has risen roughly 12% during the same period. Surprise FDA inspection at Halol unit Separately, CNBC-TV18 reported on Wednesday that a surprise inspection was underway at Sun Pharma's Halol facility, one of its largest manufacturing units, by three inspectors from the U.S. Food and Drug Administration. The Halol unit was last inspected in May 2022 and is currently under an import alert following a warning letter from the regulator. Also read | Sensex will hit 1.5 lakh by 2030 & 3 lakh by 2035! Raamdeo Agrawal makes big prediction About the drug and its target conditions Vibozilimod was being developed as a treatment for psoriasis and atopic dermatitis, two chronic inflammatory skin conditions. Psoriasis is marked by raised, scaly plaques on the skin due to accelerated skin cell growth, often affecting the elbows, knees, scalp, and trunk. Atopic dermatitis, or eczema, typically involves dry, itchy, and inflamed skin, often beginning in childhood but potentially affecting people at any age. The failure of the Phase 2 studies now casts uncertainty over SPARC's speciality drug pipeline, with investors and analysts awaiting further clarity on the company's next steps. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Business Upturn
4 days ago
- Business
- Business Upturn
SPARC shares drop nearly 20% after key drug trial fails
By Aman Shukla Published on June 4, 2025, 11:35 IST Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044). The drop came following an update from Sun Pharmaceutical Industries Limited, SPARC's collaborator, which revealed that the Phase 2 trials for Vibozilimod failed to meet their primary efficacy endpoints. The drug, which was being tested for treating moderate-to-severe psoriasis and atopic dermatitis, did not show the required 75% improvement in PASI and EASI scores by Week 16. As a result, no further trials will be conducted, marking a significant setback for both companies' specialty drug pipelines. Shares of Sun Pharma Advanced Research Company (SPARC) opened at ₹185.00 and touched an intraday low of ₹156.14, reflecting a sharp decline. The stock did not move above its opening price, indicating bearish sentiment. SPARC is currently trading closer to its 52-week low of ₹109.30, far below the 52-week high of ₹258.00. As of 11:34 AM, the shares were trading 17.95% lower at Rs 160.15. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Mint
4 days ago
- Business
- Mint
SPARC share price tumbles 20% as Sun Pharma's arm halts development of Psoriasis drug
SPARC share price: Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India's top pharmaceutical firm Sun Pharma, fell by 20% on Wednesday after unsatisfactory results from Phase 2 trials of its experimental drug SCD-044. SPARC share price opened at an intraday high of ₹ 186 apiece on the BSE, the stock touched an intraday low of ₹ 156.50 per share. SCD-044, referred to as Vibozilimod, was being developed for the treatment of psoriasis and atopic dermatitis. Nevertheless, the company announced that the drug did not achieve the primary endpoints in both of its clinical trials. Consequently, SPARC declared that it will halt further clinical development for SCD-044. Both Sun Pharma and SPARC will now evaluate the future direction of this compound. This development represents a setback, as SCD-044 was viewed as one of the more promising candidates in SPARC's specialty pipeline. In a filing with the exchange, the company noted that neither the SOLARES PsO trial nor the SOLARES AD trial achieved their primary endpoints—defined as a 75 percent reduction in PASI (Psoriasis Area and Severity Index) or EASI (Eczema Area and Severity Index) scores by Week 16. SPARC, a biopharmaceutical subsidiary of Sun Pharma that focuses on research, aims to drive innovation in fields such as oncology, neurodegenerative diseases, and inflammatory disorders. In the fourth quarter of fiscal year 2025 (Q4FY25), SPARC announced a total income of ₹ 20.96 crore, marking a 38.8% increase from ₹ 15.10 crore in the third quarter (Q3FY25). However, the loss before tax increased to ₹ 105.41 crore compared to ₹ 79.44 crore in the prior quarter, indicating a 32.7% decline in profitability. The total expenses for the quarter rose by 33.7%, reaching ₹ 126.37 crore, up from ₹ 94.54 crore in Q3. Anshul Jain, Head of Research at Lakshmishree Investments, SPARC share price has gapped down, breaching its rising moving averages, indicating a clear structure shift from bullish to bearish. After a sharp 76.88% correction in 47 weeks, the stock was attempting to form a higher low on the weekly chart, which now appears to have failed following the negative clinical trial news. With sentiment turning weak, immediate support is placed at ₹ 128. A breach of this support may accelerate further downside in the short term. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
